Payment overview · 2025
General Payments
$950.64
21 reported records · 7 companies
Healthcare provider profile · identity verified
Edward Daniel Henderson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLLINSVILLE, MS · NPI 1346222890
Verified facts
What the public records show
CMS Open Payments records show Edward Daniel Henderson, M.D. received $950.64 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $335.10 | 35.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.15 | 16.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $152.53 | 16.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.80 | 10.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.67 | 10.1% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $92.96 | 9.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.43 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $950.64 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $221.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $152.53 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $95.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.15 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.15 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 186 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 605 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 169 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 457 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 105 |
| Lisinopril | Lisinopril | 366 | 117 |
| Omeprazole | Omeprazole | 355 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 293 | 141 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 91 |
| Metformin Hcl | Metformin Hcl | 282 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 88 |
| Gabapentin | Gabapentin | 242 | 79 |
| Potassium Chloride | Potassium Chloride | 191 | 49 |
| Farxiga | Dapagliflozin Propanediol | 186 | 37 |
| Ozempic | Semaglutide | 180 | 35 |
| Carvedilol | Carvedilol | 170 | 48 |
| Montelukast Sodium | Montelukast Sodium | 167 | 53 |
| Valsartan | Valsartan | 167 | 49 |
| Mounjaro | Tirzepatide | 166 | 28 |
| Furosemide | Furosemide | 154 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 40 |
| Eliquis | Apixaban | 144 | 27 |
| Jardiance | Empagliflozin | 139 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 47 |
| Trazodone Hcl | Trazodone Hcl | 131 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 44 |
| Buspirone Hcl | Buspirone Hcl | 124 | 34 |
| Losartan Potassium | Losartan Potassium | 124 | 48 |
| Ezetimibe | Ezetimibe | 123 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 41 |
| Mirtazapine | Mirtazapine | 105 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 104 | 32 |
| Metformin Hcl Er | Metformin Hcl | 101 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 28 |
| Famotidine | Famotidine | 89 | 30 |
| Trulicity | Dulaglutide | 88 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 37 |
| Sertraline Hcl | Sertraline Hcl | 83 | 23 |
| Allopurinol | Allopurinol | 82 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 26 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 80 | 13 |
| Linzess | Linaclotide | 79 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Januvia | Sitagliptin Phosphate | 73 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 18 |
| Lactulose | Lactulose | 65 | 24 |
| Myrbetriq | Mirabegron | 64 | 11 |
| Spironolactone | Spironolactone | 64 | 20 |
| Fluconazole | Fluconazole | 61 | 23 |
| Rybelsus | Semaglutide | 59 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 17 |
| Promethazine Hcl | Promethazine Hcl | 58 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 36 |
| Methocarbamol | Methocarbamol | 55 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 14 |
| Aripiprazole | Aripiprazole | 53 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Azelastine Hcl | Azelastine Hcl | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | 15 |
| Vascepa | Icosapent Ethyl | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 18 |
| Valacyclovir | Valacyclovir Hcl | 41 | 11 |
| Cefuroxime | Cefuroxime Axetil | 39 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 12 |
| Azithromycin | Azithromycin | 37 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 30 |
| Topiramate | Topiramate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Kerendia | Finerenone | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Mupirocin | Mupirocin | 34 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Atenolol | Atenolol | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 11 |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 11 |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Nystatin | Nystatin | 22 | 11 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 12 |
| Meloxicam | Meloxicam | 20 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $950.64 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, EVENITY, FARXIGA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error